Date: 2013-05-31
Type of information: Licensing agreement
Compound: diagnostic test based on FGFR-TACC fusion genes
Company: Qiagen (The Netherlands) Columbia University (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: glioblastoma
Details: * On May 31, 2013, Qiagen has announced an agreement adding promising new biomarkers involving glioblastoma to its portfolio of potential companion diagnostics.The company has entered into an exclusive worldwide licensing option on FGFR-TACC fusion genes with Columbia University in New York. Qiagen intends to develop this biomarker into a diagnostic test for routine use in diagnostic workups, which may enable doctors to identify glioblastoma patients who could benefit from targeted treatments now under development.
Financial terms:
Latest news:
